+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Small-Cell Lung Cancer - Pipeline Review, H2 2019

  • ID: 4901393
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 1225 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bavarian Nordic A/S
  • EpicentRx Inc
  • Incyte Corp
  • Nippon Kayaku Co Ltd
  • Seneca Therapeutics Inc
  • MORE
Small-Cell Lung Cancer - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2019, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.

Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 61, 43, 6, 39, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 2 and 1 molecules, respectively.

Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bavarian Nordic A/S
  • EpicentRx Inc
  • Incyte Corp
  • Nippon Kayaku Co Ltd
  • Seneca Therapeutics Inc
  • MORE
Introduction
Small-Cell Lung Cancer - Overview
Small-Cell Lung Cancer - Therapeutics Development
Small-Cell Lung Cancer - Therapeutics Assessment
Small-Cell Lung Cancer - Companies Involved in Therapeutics Development
Small-Cell Lung Cancer - Drug Profiles
Small-Cell Lung Cancer - Dormant Projects
Small-Cell Lung Cancer - Discontinued Products
Small-Cell Lung Cancer - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Small-Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2019

List of Figures
Number of Products under Development for Small-Cell Lung Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Advanced Accelerator Applications SA
  • Advenchen Laboratories LLC
  • Aeglea BioTherapeutics Inc
  • Akeso Biopharma Inc
  • Allogene Therapeutics Inc
  • Altor Bioscience LLC
  • Amgen Inc
  • Andarix Pharmaceuticals Inc
  • Apollomics Inc
  • Aposense Ltd
  • Aprea Therapeutics AB
  • Ascenta Therapeutics Inc
  • Ascentage Pharma Group International
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Auransa Inc
  • Autolus Therapeutics Plc
  • Bavarian Nordic A/S
  • BeiGene Ltd
  • Beta Pharma Inc
  • BeyondSpring Inc
  • Biogenera SpA
  • BioLineRx Ltd
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Carrick Therapeutics UK Ltd
  • Celldex Therapeutics Inc
  • Checkpoint Therapeutics Inc
  • Chiome Bioscience Inc
  • Chipscreen Biosciences Ltd
  • Coherent Biopharma
  • Cotinga Pharmaceuticals Inc
  • CSPC Pharmaceutical Group Ltd
  • CStone Pharmaceuticals Co Ltd
  • Cumberland Pharmaceuticals Inc
  • Daiichi Sankyo Co Ltd
  • Eisai Co Ltd
  • Eli Lilly and Co
  • EpicentRx Inc
  • Esanex Inc
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corp
  • G1 Therapeutics Inc
  • GlaxoSmithKline Plc
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Hanmi Pharmaceuticals Co Ltd
  • Harpoon Therapeutics Inc
  • Hillstream BioPharma Inc
  • Horizon Therapeutics PLC
  • Hutchison MediPharma Ltd
  • ImmunityBio Inc
  • Immunocore Ltd
  • Immunomedics Inc
  • ImmunSYS Inc
  • Incyte Corp
  • Innovent Biologics Inc
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc
  • Lee's Pharmaceutical Holdings Ltd
  • Lixte Biotechnology Holdings Inc
  • MabVax Therapeutics Holdings Inc
  • Merck & Co Inc
  • Merck KGaA
  • Moderna Therapeutics Inc
  • Mologen AG
  • MultiVir Inc
  • Mundipharma EDO GmbH
  • Nektar Therapeutics
  • NewBio Therapeutics Inc
  • NewLink Genetics Corp
  • Ningbo Wenda Pharma
  • Nippon Kayaku Co Ltd
  • Northlake International LLC
  • Novartis AG
  • NOX Pharmaceuticals Inc
  • OncoFusion Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Oryzon Genomics SA
  • Oxford BioTherapeutics Ltd
  • Pfizer Inc
  • Phanes Therapeutics Inc
  • Pharma Mar SA
  • Plexxikon Inc
  • Plus Therapeutics Inc
  • Rafael Pharmaceuticals Inc
  • Recombio SL
  • Rexahn Pharmaceuticals Inc
  • Rgenix Inc
  • SciTech Development LLC
  • Seattle Genetics Inc
  • SELLAS Life Sciences Group Inc
  • Seneca Therapeutics Inc
  • Shanghai Henlius Biotech Inc
  • Shanghai Junshi Bioscience Co Ltd
  • Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
  • Sierra Oncology Inc
  • Sorrento Therapeutics Inc
  • Sound Biologics
  • Starpharma Holdings Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Syros Pharmaceuticals Inc
  • Tactical Therapeutics Inc
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Targovax ASA
  • Tarveda Therapeutics Inc
  • Telomium SAS
  • Tmunity Therapeutics Inc
  • Trillium Therapeutics Inc
  • Trovagene Inc
  • United Therapeutics Corp
  • Woomera Therapeutics Inc
  • Xbrane Biopharma AB
  • Xcovery Holding Company LLC
  • Xencor Inc
  • Y-Biologics
  • Zensun (Shanghai) Sci & Tech Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll